Gastric cancer is the second-leading cause of cancer-related mortality worldwide. There is significant geographic variation in the burden of the disease: incidence and mortality are notably high in East Asia, China, Eastern Europe, and Latin America, whereas the disease is no longer as common in North America and Western Europe. Globally, there has been a steady decline in incidence over the past 50 years. This is mostly attributable to the decline in prevalence of H. pylori infections, a decline in tobacco use, and improvements in food preservation and diet.
Market Snapshot
The gastric cancer market is projected to reach $2.1bn in value by 2026, with growth driven by immunotherapies.
Cyramza plays an important role in the second-line treatment of metastatic and distant relapse gastric cancer.
Despite declining incidence proportions, the number of cases is forecasted to increase and prognosis remains poor.
Cyramza's dominance in second-line advanced gastric cancer is being challenged as immunotherapies enter the market.
Bavencio will target the maintenance setting in order to avoid direct competition with established immunotherapies.
Access restrictions are moderate in gastric cancer and GIST.
Key Topics Covered:
Forecast: Gastric Cancer
Executive Summary
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Abraxane
Product Profile (Late Stage): Bavencio
Product Profile: Cyramza
Product Profile: Herceptin
Product Profile: Keytruda
Product Profile: Opdivo
Product Profile (Late Stage): Andeclaximab
Product Profile (Late Stage): Apatinib
Treatment: Gastric Cancer
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Epidemiology: Gastric Cancer In The Us, Japan, And 5EU
Discover new ways to make your skin BLOOM! Beekman 1802's top selling skin barrier-building formula, Bloom Cream Daily Face Moisturizer, is now available in two NEW formats that will make blooming even better! Introducing the Bloom Cream in a Tube...
ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of A5374, a phase 1/2a study evaluating the safety, tolerability, and antiviral effect of a novel combination regimen that includes...
PureTalk, a nationwide cell phone service provider offering premium wireless service at a fair price on the nation's most dependable 5G network, today celebrates over $100,000 customer donations to the America's Warrior Partnership (AWP). Since...
On 5 April 2024, SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Board of Directors, with the support of the authorization granted by the annual general meeting held on 17 May 2023, had resolved on a rights issue of units,...
Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced that Galentm Breast HER2 has been named a bronze winner of the 2024 Edison Awards in the Diagnostic Technologies category. The awards, named after inventor...